调强放疗联合紫杉醇+顺铂治疗晚期非小细胞肺癌临床疗效

Clinical efficacy of intensity modulated radiation therapy combined with paclitaxel+cisplatin in the treatment of advanced non-small cell lung cancer

目的探讨调强放疗联合紫杉醇+顺铂治疗晚期非小细胞肺癌的临床疗效。方法将80例晚期非小细胞肺癌患者按照治疗方案不同分为联合组与对照组,各40例。两组均给予调强放疗,联合组在此基础上联合紫杉醇+顺铂治疗。治疗前及治疗8周末比较两组血清肿瘤标志物水平及肺功能,比较两组临床疗效及不良反应发生率。结果治疗8周末两组血清糖类抗原125、癌胚抗原、胃泌素释放肽前体水平均显著低于治疗前(P<0.01),联合组显著低于对照组(P<0.01)。治疗前及治疗8周末两组肺活量、1秒用力呼气量、最大呼气中期流量水平比较差异均无统计学意义(P>0.05),联合组与对照组比较差异无统计学意义(P>0.05)。联合组治疗总有效率显著高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论调强放疗联合紫杉醇+顺铂治疗晚期非小细胞肺癌患者临床疗效显著,可降低患者血清肿瘤标志物水平,对患者肺功能无明显负面影响,安全性高。

Objective To investigate the clinical efficacy of intensity modulated radiation therapy(IMRT)combined with paclitaxel+cisplatin(TP)in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 80 patients with advanced NSCLC were divided into combination group and control group according to different treatment regimens,with 40 cases in each group.Both groups were given IMRT,and the combination group was treated with TP on this basis.Before treatment and 8 weeks after treatment,the levels of serum tumor markers and lung function were compared between the two groups,and the clinical efficacy and incidence of adverse reactions were compared between the two groups.Results After 8 weeks of treatment,the carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),and pro-gastrin-releasing peptide(Pro-GRP)in the two groups were significantly lower than those before treatment(P<0.01),and the combination group was significantly lower than the control group(P<0.01).Before treatment and after 8 weeks of treatment,there was no significant difference in the levels of forced vital capacity(FVC),forced expiratory volume in one second(FEV1),and maximal mid expiratory flow(MMEF)between the two groups(P>0.05),and there was no significant difference between the combination group and the control group(P>0.05).The total effective rate of the combination group was significantly higher than that of the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusions IMRT combined with TP regimen has significant clinical efficacy in the treatment of patients with advanced NSCLC,can reduce the level of serum tumor markers,has no significant negative impact on lung function of patients,and has high safety.